Skip to main content
. Author manuscript; available in PMC: 2019 Dec 5.
Published in final edited form as: Cell Rep. 2019 Nov 26;29(9):2556–2564.e3. doi: 10.1016/j.celrep.2019.10.092

Figure 3. Engagement of PD-1 in the Subacute Phase Is Required for Durable Control of LCMV Infection.

Figure 3.

(A) Plasma viral RNA load in LCMV-c13-infected B6 mice treated with anti-PD-L1 on 8–22 dpi (red dots, same as Figure 1) or 23–37 dpi (blue dots). Data are pooled from 5 experiments shown with median.

(B–D) Expression of CD4, CD8, CD44, PD-1, LAG3, and LCMV-gp33-specific TCR by splenocytes (B and C) and peripheral blood mononuclear cells (D) on day 37 of LCMV-c13 infection. Representative plots are shown with median ± SD from at least 2 experiments.